Clinical guidance on the use of esketamine nasal spray for patients with treatment resistant depression: A European Delphi consensus report.
European Neuropsychopharmacology July 17, 2026 Allan H. Young, Bernhard T Baune, Beatrice Benatti et al.
Esketamine nasal spray (NS) is an established treatment for patients with treatment resistant depression (TRD). To further optimise real-world outcomes, consensus is needed regarding strategies to enhance patient outcomes and decision-making factors for pivotal timepoints in esketamine NS treatment. This modified Delphi panel (3 rounds) established expert consensus (≥80% agreement) from 30...
DOI: 10.1016/j.euroneuro.2026.112907 (opens in new tab)
Full text (opens in new tab)
Esketamine nasal spray
Assessment patient outcome
Decision-making shared
Delphi method
+1